Quick Answer
Avalo Therapeutics, Inc. reported Total Assets of $116.46 million for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -22.7% in Total Assets from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $5.45 million | Q1 2016: $16.93 million | Q2 2016: $13.17 million | Q3 2016: $9.58 million | Q1 2017: $3.56 million | Q2 2017: $6.05 million | Q3 2017: $28.20 million | Q1 2018: $65.36 million | Q2 2018: $62.15 million | Q3 2018: $67.61 million | Q1 2019: $74.87 million | Q2 2019: $59.62 million | Q3 2019: $57.19 million | Q1 2020: $44.12 million | Q2 2020: $69.20 million | Q3 2020: $59.19 million | Q1 2021: $63.35 million | Q2 2021: $64.09 million | Q3 2021: $95.36 million | Q1 2022: $61.90 million | Q2 2022: $32.22 million | Q3 2022: $36.55 million | Q1 2023: $36.24 million | Q2 2023: $24.24 million | Q3 2023: $29.27 million | Q1 2024: $123.73 million | Q2 2024: $108.31 million | Q3 2024: $98.46 million | Q1 2025: $138.52 million | Q2 2025: $126.58 million | Q3 2025: $125.10 million.
- Over the full 12 years of available data (2014 to 2025), Avalo Therapeutics, Inc.'s Total Assets has grown by 845.5%.
- Historical annual values: Fiscal year 2025: $116.46 million | Fiscal year 2024: $150.73 million | Fiscal year 2023: $20.99 million | Fiscal year 2022: $33.37 million | Fiscal year 2021: $80.21 million | Fiscal year 2020: $43.76 million | Fiscal year 2019: $36.11 million | Fiscal year 2018: $70.25 million | Fiscal year 2017: $42.81 million | Fiscal year 2016: $5.77 million | Fiscal year 2015: $21.66 million | Fiscal year 2014: $12.32 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: